AnaptysBio Inc's stock soared 5.23% during Monday's intraday trading session, following a positive analyst update from Truist Securities.
The surge came after Truist Securities raised its price target on AnaptysBio to $50 from $36, while maintaining a Hold rating on the stock. This significant upward revision in the price target likely provided a catalyst for investor optimism, driving the share price higher.